Temozolomide and Thalidomide for Advanced Leiomyosarcoma
Author Information
Author(s): Michelle S. Boyar, Mary Hesdorffer, Mary Louise Keohan, Zhezhen Jin, Robert N. Taub
Primary Institution: Columbia University Medical Center
Hypothesis
Temozolomide is the active agent in this regimen and should be further studied.
Conclusion
The combination of temozolomide and thalidomide provided disease stabilization in a subset of patients with advanced leiomyosarcoma.
Supporting Evidence
- Two patients (10%) had partial responses.
- Five patients (24%) had stable disease for at least six months.
- The median overall survival was 9.5 months.
Takeaway
Doctors tested a combination of two medicines on patients with a type of cancer called leiomyosarcoma. Some patients felt better for a while, but not everyone got better.
Methodology
This was a phase II single-institution trial where patients received temozolomide and thalidomide until disease progression or unacceptable toxicity.
Limitations
The study was limited to a small number of patients and had a low overall response rate.
Participant Demographics
Median age was 60 years, with 92% female and 8% male participants.
Statistical Information
Confidence Interval
95% CI 7–28 months for overall survival
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website